Development of targeted therapies in treatment of glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Glioblastoma (GBM) is a highly lethal brain tumor with limited therapeutic options.
• Standard treatments offer modest survival benefits, highlighting the need for novel therapeutic strategies.
• Targeted therapy, focusing on specific molecular pathways, represents a rapidly evolving area in oncology.

Purpose of the Study:

• To provide an up-to-date review of current targeted therapies for Glioblastoma.
• To discuss the molecules targeted and their roles in GBM proliferation, survival, and invasiveness.
• To examine the challenges and conflicting results in the development of targeted GBM therapies.

Main Methods:

• Literature review of preclinical and clinical studies on Glioblastoma targeted therapy.
• Analysis of signal transduction pathways critical for GBM cell function.
• Evaluation of drugs targeting specific molecules in ongoing clinical trials.

Main Results:

• Numerous molecular targets involved in GBM pathogenesis have been identified.
• Targeted inhibitors are entering or are in clinical trials for GBM treatment.
• Conflicting results exist in preclinical and clinical studies, indicating developmental challenges.

Conclusions:

• Targeted therapies offer a promising avenue for Glioblastoma treatment.
• Further research is needed to overcome challenges and resolve conflicting study outcomes.
• Optimizing targeted therapy development is crucial for improving patient survival in GBM.